Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patterns in detection of recurrence among patients treated for breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Estrogen receptor positive (ER+) breast cancer constitutes almost 85% of all breast cancer patients and are a genetically highly heterogenic group. Data on the association of somatic alterations to outcome and prognosis are however sparse. In this neoadjuvant endocrine phase II trial including postmenopausal breast cancer patients with ER+, HER2 normal breast cancer, we investigated the rate of pathogenic mutations before and after treatment as well as the association with treatment response and survival.

METHODS: Pretreatment and posttreatment tumour samples from 109 patients treated with neoadjuvant letrozole were collected and analysed with Next Generation Sequencing utilizing a panel of 12 genes (ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1). Residual disease was assessed by a modified Miller Payne scale and the Residual Cancer Burden index. Survival data were collected prospectively.

RESULTS: Among the 109 patients, 52 had at least one pathogenic mutation in the pretreatment sample and 60 in the posttreatment sample. The most frequently mutated gene was PIK3CA, followed by EGFR and KRAS. Twelve different pathogenic PIK3CA mutations were identified, primarily in exon 20 and exon 9. An altered PIK3CA mutation profile from the pre- to the posttreatment specimen was significantly associated to improved pathological outcome. Overall and Disease-Free Survival benefits in PIK3CA mutated patients was observed.

CONCLUSION: Considerable heterogeneity was identified both among patients and between pre- and posttreatment samples. PIK3CA has the potential to be a predictive biomarker. To further assess the implications of a treatment related altered PIK3CA mutation profile, more data are needed.

Original languageEnglish
JournalBreast Cancer Research and Treatment
Volume184
Issue number1
Pages (from-to)123-133
Number of pages11
ISSN0167-6806
DOIs
Publication statusPublished - Nov 2020

ID: 61369090